Parallel to finishing her PhD in epidemiology and health systems management at the University of Basel, Anna also studied medicine and conducted research at Harvard and University of Zurich medical schools. Before her role as a medical director in Klinik Hirslanden and her current role as managing director of the Longevity Center in Switzerland, she attended executive courses at Harvard Business School and finished the International Directors Program at INSEAD. Apart from mentoring at the ETH and being faculty in the University of St. Gallen Executive School, she gives talks on sustainable health, preventive medicine and longevity for the UN and the World Economic Forum among others.

Thierry works at Oracle Corporation where he represents and coordinates the Insight, Innovation, Industry and Enterprise Architecture teams for EMEA South, Switzerland, Austria and the Scandinavian countries. Before joining Oracle, Thierry worked at McKinsey & Company in Europe, North America and Africa and was a visiting researcher at NEC Tokyo. Prior to that he worked for two Swiss banks in the IT and strategy departments. He holds a Ph.D. in Computer Science and Artificial Intelligence from the University of Zurich and an M.Sc. in Computer Science from ETH Zurich. In his spare time, he spends as much time as possible with his family and outdoors (e.g. training for triathlons), or he programs web and machine learning applications.

Andrew is a retired Olympic athlete and Digital Health and Human Performance Technology Entrepreneur. Currently Andrew works as the Chief Product Officer for Prenetics EMEA. Having competed internationally for 15 years on Team GB, Andrew then went on to win an Olympic bronze medal for the 4x400m relay at the Beijing 2008 Olympic Games. As Andrew’s competitive career came to a close, he joined the founding team of personal genetics company DNAfit, building the world’s first digital platform to help everybody understand how their DNA impacts exercise, nutrition, stress and sleep response. After DNAfit was acquired by the Prenetics group in 2018, Andrew helped grow the EMEA business from a startup to a team of over 700, culminating in a successful Nasdaq listing at >$1bn valuation in 2022.